PAP therapy saves lives in heart patients: ResMed

Positive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce mortality rates by up to 38%, analysis from ResMed (ASX:RMD) suggests.

GI Dynamics lines up new CEO

Seasoned medical device executive Michael Dale will take over from Stuart A Randle as CEO of GI Dynamics (ASX:GID) from next month.

Phylogica awarded three new peptide patents

Phylogica (ASX:PYC) has added a Japanese patent and two more from the US to its intellectual property portfolio.

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

AusBiotech fully supports the Australian Greens' moving of an amendment in the Senate to put in place quarterly payments for small and medium-size businesses eligible for an R&D Tax Incentive refund.

AFL approves use of Regeneus's HiQCell

The AFL has added Regeneus (ASX:RGS) HiQCell to a list of approved treatments for injuries including impact-related osteoarthritis and tendonitis.

Mesoblast posts wider loss, details product roadmap

Mesoblast (ASX:MSB) has announced its financial results for FY14 and laid out a five-pronged strategy for commercialising its key regenerative medicine products.

Vaxxas recognised by WEF for vaccine tech

Vaxxas has been selected as a 2015 Technology Pioneer by the World Economic Forum for its patch-based vaccine delivery technology.

ResMed scores initial win in ITC case against BMC

A US ITC judge has found in favour of ResMed (ASX:RMD) in the company's patent infringement action against China's BMC Medical, and has recommended an import ban.

Tech Transfer Summit set to be held next week in Adelaide

Following on from a successful first-ever Tech Transfer Summit (TTS) Australia in 2013, the TTS Global Initiative and AusBiotech are pleased to confirm the Australian chapter will be returning to South Australia next week with the support of major partner BioSA.

Alchemia, Mesoblast hire new CFOs

Former Mesoblast (ASX:MSB) CFO Jenni Pilcher has joined Alchemia (ASX:ACL), while former Novartis ANZ CFO 

Paul Hodgkinson will fill the vacant position at Mesoblast.

Orthocell aces tennis elbow trial

Orthocell's (ASX:OCC) autologous cell therapy Ortho-ATI improved grip strength in chronic tennis elbow patients by an average of 207% at 4.5 years post-treatment.

Consultation begins for new Industry Skills Fund

The federal government's new $476 million Industry Skills Fund is due to commence 1 January 2015 and a consultation has commenced in preparation, which includes webinars, a discussion paper and a digital questionnaire.

Bionomics posts maiden profit for FY14

Income from Bionomics' (ASX:BNO) licensing deal with Merck for Alzheimer's candidate BNC375 helped the company report its first post-tax operating profit for the last financial year.

Starpharma loss widens during "important" year

Starpharma put a chunk of its free cash to good use during FY14, making progress with its drug delivery, antimicrobial and agribusiness programs.

ResMed launches new sleep breathing devices, platform

ResMed (SSX:RMD) has unveiled its new Air Solutions sleep-disordered breathing therapy platform, including the flagship AirSense 10 positive airway pressure devices.